Skip to content

Epidemiology and global burden

TL;DR — GBD 2021 estimated 260 million people (95% uncertainty interval [UI] 227–298 million) living with asthma in 2021; the age-standardized prevalence fell 40.0% from 1990, yet absolute cases rose after 2005 and are forecast to reach 275 million (224–330 million) in 2050 because of population growth (GBD 2021 Asthma and Allergic Diseases Collaborators 2025, PMID 40147466). Questionnaire surveillance shows far wider geographic variation than modelled national estimates: ISAAC current wheeze ranged from 0.8% to 32.6% in adolescents and 2.4% to 37.6% in children, with severe symptoms disproportionately concentrated in lower-income settings (Lai 2009, PMID 19237391). Asthma is often more prevalent in affluent settings but more lethal or severe where essential inhaled corticosteroids, reliable diagnosis and acute care are least accessible. Boys predominate before puberty and women after puberty; incidence and remission vary across the life course, so childhood asthma is not the whole disease (Eagan 2005, PMID 15971386). Declining age-standardized rates therefore coexist with persistent inequity, large absolute burden and preventable deaths.

What is being counted

Asthma epidemiology depends on the case definition. Population instruments count different constructs:

Measure What it captures Principal bias
Current wheeze questionnaire Symptoms in a defined recent period Includes non-asthma wheeze; misses non-wheeze phenotypes
Ever physician-diagnosed asthma Access to and behavior of health systems Underdiagnosis where testing and care are scarce; overdiagnosis where symptoms are labeled empirically
Current treated asthma Diagnosis plus access/adherence Excludes untreated disease and remission
Objective survey definition Symptoms plus spirometry, reversibility or challenge More specific but expensive and difficult at global scale
Administrative codes Encounters coded as asthma Captures health-care utilization and coding practice, not community prevalence
GBD model Harmonized estimates from surveys, records and covariates Depends on source coverage and model assumptions in data-sparse countries (GBD 2015 Chronic Respiratory Disease Collaborators 2017, PMID 28822787)

Because asthma lacks a single diagnostic gold standard, comparisons are most credible when age group, questionnaire, objective-test rules and calendar period are identical (Asher 2020, PMID 32972987). A change in “prevalence” can reflect biology, awareness, access, questionnaire wording or diagnostic substitution.

Global burden: current quantitative anchors

Metric Estimate Population, year and method Source
People living with asthma 260 million (95% UI 227–298 million) 204 countries/territories, GBD 2021 Bayesian meta-regression from 389 asthma data sources GBD 2021 Collaborators 2025, PMID 40147466
Cases in 1990 → 2005 → 2021 287 million (250–331) → 238 million (209–272) → 260 million (227–298) GBD 2021 GBD 2021 Collaborators 2025, PMID 40147466
Age-standardized prevalence 5,568.3 → 3,340.1 per 100,000, a 40.0% fall, 1990–2021 GBD 2021 GBD 2021 Collaborators 2025, PMID 40147466
Forecast cases in 2050 275 million (224–330 million) GBD forecast using SDI, pollution and smoking; uncertainty includes stable or falling age-standardized prevalence GBD 2021 Collaborators 2025, PMID 40147466
Highest regional age-standardized DALY rate, 2021 South Asia: 465.0 (357.2–648.9) per 100,000 GBD 2021 GBD 2021 Collaborators 2025, PMID 40147466
Modifiable-risk share of DALYs 29.9% High BMI, occupational asthmagens, smoking and NO2 modeled GBD 2021 Collaborators 2025, PMID 40147466
1990–2019 age-standardized change prevalence −24.05%; mortality −51.3%; DALY rate −42.55% GBD 2019 analysis Wang 2023, PMID 37353829
Global asthma deaths, 2015 0.40 million (0.36–0.44 million) Cause-of-death ensemble models GBD 2015 Collaborators 2017, PMID 28822787

The 1990–2021 prevalence decline in the latest GBD release is larger than the 1990–2019 decline reported from GBD 2019. These estimates should be shown side by side, not blended: each release revises sources, definitions and models (GBD 2021 Asthma and Allergic Diseases Collaborators 2025, PMID 40147466; Wang 2023, PMID 37353829).

Childhood prevalence: standardized surveys reveal heterogeneity

ISAAC Phase Three surveyed 798,685 adolescents aged 13–14 years in 233 centers across 97 countries and 388,811 children aged 6–7 years in 144 centers across 61 countries (Lai 2009, PMID 19237391).

Indicator Ages 13–14 Ages 6–7 Source
Range of current wheeze 0.8% Tibet to 32.6% Wellington 2.4% Jodhpur to 37.6% Costa Rica Lai 2009, PMID 19237391
Range of severe-asthma symptoms 0.1% Pune to 16.0% Costa Rica 0% Pune to 20.3% Costa Rica Lai 2009, PMID 19237391
Global current-asthma symptom prevalence 14.1% 11.7% ISAAC synthesis, Mallol 2013, PMID 22771150

Higher-income centers tended to have more current wheeze, but among children who wheezed, severe symptoms were more common in less affluent centers (Lai 2009, PMID 19237391). That inversion is central: prevalence and failure to prevent severe outcomes are different epidemiologic questions.

Repeating ISAAC approximately seven years later covered 193,404 younger children and 304,679 adolescents. Increases were about twice as common as decreases across allergic-disease outcomes, but asthma symptoms decreased more often in high-prevalence adolescent centers; trends were mixed even within countries (Asher 2006, PMID 16935684).

The standardized questionnaire enabled comparison at unprecedented scale, but it measured symptom prevalence rather than objectively verified asthma. Its strength is consistent ascertainment; its limitation is imperfect disease specificity (Asher 2020, PMID 32972987).

Life-course distribution

Asthma can begin, remit and relapse at any age.

Pattern Quantitative evidence Interpretation
Adult incidence Pooled 4.6 per 1,000 person-years in women and 3.6 in men; general-population cohorts 5.9 and 4.4, respectively Adult-onset asthma is common and modestly female-predominant (Eagan 2005, PMID 15971386)
Childhood and mid-adult peaks Southern Taiwan: highest incidence at ages 0–12 and 36–40; 25,377 adults contributing 949,807 person-years A U-shaped onset distribution; recall and questionnaire diagnosis limit transportability (Wu 2014, PMID 25387792)
Persistence/relapse >52% persistence or relapse after onset by age 12 in the Taiwan survey Childhood onset does not imply permanent disease, but remission is not assured (Wu 2014, PMID 25387792)
Sex crossover Male excess before puberty; female excess after puberty Hormonal, airway-size, exposure and diagnostic factors probably interact; no single mechanism explains the crossover (Eagan 2005, PMID 15971386)
Hospitalization sex ratio Canadian 1994–1997 records: female:male hospitalization incidence ratio peaked at 2.8 at ages 25–34 Morbidity as well as prevalence reverses after childhood (Chen 2003, PMID 12654413)

Incidence estimates in older adults are especially vulnerable to COPD misclassification, and late-life “new asthma” should not be inferred from an administrative code alone (Eagan 2005, PMID 15971386).

Severe asthma and attack burden

Severe asthma is a small fraction of asthma but a disproportionate source of attacks, systemic-steroid exposure and cost. Definitions differ between treatment intensity, uncontrolled status and specialist confirmation, making prevalence estimates difficult to compare (Merhej 2023, PMID 37464114).

For children, asthma remains among the highest-ranked chronic causes of disability. A global review placed it among the top ten causes of DALYs at ages 5–14 and reported child asthma death rates ranging from 0 to 0.7 per 100,000 across countries (Asher 2014, PMID 25299857).

Deaths are rare relative to prevalence but epidemiologically important because many reflect modifiable failures: inadequate controller therapy, delayed recognition, excess reliance on reliever medication, and barriers to emergency care (Pérez-Padilla 2008, PMID 18797736).

Inequality is visible at every level

Asthma disparities reflect exposure, susceptibility, diagnosis, treatment and rescue systems rather than race or income as biological causes.

Inequality axis Evidence What the comparison can and cannot establish
Country income Severe symptoms among current wheezers were more frequent in lower-income ISAAC centers Ecological association; does not isolate access from environment (Lai 2009, PMID 19237391)
US race under equal insurance category Medicaid 2019: hospitalization 1.2% Black vs 0.5% White children; ED visit 8.0% vs 3.4%; adjusted OR 2.45 (95% CI 2.23–2.69) and 2.42 (2.33–2.51) Coverage alone did not eliminate differences; claims cannot measure every exposure or care-quality pathway (Smith 2024, PMID 38752291)
US hospitalization trends 2012–2020 ranges: 9.8–36.7 per 10,000 Black children vs 2.2–9.4 White children; rates declined similarly, leaving the gap Falling overall rates do not imply equity (Binney 2024, PMID 39298796)
Rurality and access US surveillance found differences in attacks, ED/urgent care and mortality across sociodemographic and urban–rural groups Descriptive surveillance identifies where, not the causal mechanism (Pate 2021, PMID 34529643)
Neighborhood conditions Low-income urban children face higher mold, pest, smoke, chemical and pollution exposures plus care barriers Exposures cluster and are hard to separate statistically (Simoneau 2023, PMID 36861771)

Historical redlining, housing disrepair, traffic and industrial placement, caregiver stress, pharmacy access and discriminatory care can converge in the same patient. Treating these as interchangeable “socioeconomic status” conceals actionable mechanisms (Simoneau 2023, PMID 36861771).

Mortality: falling rates, unfinished prevention

GBD 2015 estimated 0.40 million asthma deaths (95% UI 0.36–0.44 million) in 2015, 26.7% fewer than in 1990, while population aging and source uncertainty complicate the trend (GBD 2015 Collaborators 2017, PMID 28822787).

GBD 2021 subsequently estimated 436,000 deaths in 2021; the coexistence of declining age-standardized mortality and a large absolute death count is not contradictory (GBD 2021 Collaborators 2025, PMID 40147466).

National patterns show residual preventable risk. In Brazil, 5,014 people under 20 died from asthma during 1996–2015; the rate fell 59.8%, from 0.57 to 0.21 per 100,000, yet out-of-hospital mortality did not significantly decline and adolescents had 1.5-fold higher odds of dying outside hospital than children under ten (Pitchon 2020, PMID 31009618).

In the United States, the proportion of asthma deaths occurring at home rose from 23% in 2000–2001 to 36% in 2018–2019 even as overall mortality declined (Kilpatrick 2024, PMID 37848103). Place of death is not a direct measure of preventability, but it raises questions about recognition, action plans, access and timeliness.

Environmental and attributable burden

GBD 2021 attributed 29.9% of asthma DALYs to four modeled modifiable risks. High BMI contributed the largest age-standardized DALY rate, 39.4 (95% UI 19.6–60.2) per 100,000, followed by occupational asthmagens at 20.8 (16.7–26.5) per 100,000; high-BMI attribution was greatest in high-SDI settings and occupational attribution in low-SDI settings (GBD 2021 Collaborators 2025, PMID 40147466).

GBD 2019 estimated the fractions of global asthma DALYs attributable to high BMI, smoking and occupational asthmagens as 16.94%, 9.87% and 8.82%, respectively (Wang 2023, PMID 37353829). These are modeled population-attributable fractions, not proportions of individual cases with a single cause.

Traffic-related air pollution is associated with incident childhood asthma in systematic review and meta-analysis, but exposure metrics, pollutants and residual socioeconomic confounding vary across studies (Khreis 2017, PMID 27881237).

Extreme weather and outdoor pollution are associated with asthma outcomes, increasingly linking climate exposure to surveillance and preparedness rather than only long-term etiology (Agache 2024, PMID 38311978).

Economic burden

Cost-of-illness evidence is heterogeneous enough that currency-adjusted totals should not be casually compared. A 68-study systematic review found hospitalization and medication were leading direct-cost drivers, while missed work and school dominated indirect costs (Bahadori 2009, PMID 19454036).

Across countries, annual per-person costs differ both because true care patterns differ and because studies include different combinations of direct medical, informal-care, productivity and premature-mortality costs (Ehteshami-Afshar 2016, PMID 26688525).

Uncontrolled and severe disease concentrate spending. Cost reduction therefore depends on preventing attacks and improving access, not merely lowering unit prices of controller medication.

Surveillance gaps

  • The most comparable worldwide child symptom data were collected mainly in 2000–2003; later Global Asthma Network work improves recency but coverage remains uneven (Asher 2020, PMID 32972987).
  • Adult prevalence is less consistently standardized internationally than child ISAAC surveillance.
  • Vital registration is incomplete in many of the settings with highest modeled mortality; GBD estimates depend more strongly on covariates there (GBD 2015 Collaborators 2017, PMID 28822787).
  • Administrative trends may reflect coding transitions, insurance changes or admission thresholds.
  • “Severe asthma” prevalence cannot be compared without reporting whether diagnosis, adherence and comorbidity were verified.

Open questions

  • Why did age-standardized asthma prevalence fall 40.0% in GBD 2021 while standardized symptom surveys show mixed local trends, and how much is model revision versus real epidemiology? (GBD 2021 Collaborators 2025, PMID 40147466; Asher 2020, PMID 32972987)
  • Which components of the Black–White pediatric acute-care gap change after equalizing controller access, housing remediation and continuity of care? Coverage-category adjustment leaves an adjusted OR above 2 (Smith 2024, PMID 38752291).
  • What explains persistent at-home asthma deaths while overall US mortality declines? (Kilpatrick 2024, PMID 37848103)
  • Can comparable, objective adult surveillance be implemented across low-, middle- and high-income settings without losing the reach of questionnaire surveys?
  • Which interventions reduce the high severe-symptom fraction in lower-income countries even when symptom prevalence is not high? (Lai 2009, PMID 19237391)

References

  1. GBD 2021 Asthma and Atopic Dermatitis Collaborators. Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050. Lancet Respir Med. 2025. PMID 40147466
  2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for COPD and asthma, 1990–2015. Lancet Respir Med. 2017. PMID 28822787
  3. Wang Z, et al. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019. Respir Res. 2023. PMID 37353829
  4. Asher MI, et al. Trends in worldwide asthma prevalence. Eur Respir J. 2020. PMID 32972987
  5. Lai CKW, et al. Global variation in the prevalence and severity of asthma symptoms: ISAAC Phase Three. Thorax. 2009;64:476-483. PMID 19237391
  6. Mallol J, et al. The International Study of Asthma and Allergies in Childhood Phase Three: a global synthesis. Allergol Immunopathol. 2013. PMID 22771150
  7. Asher MI, et al. Worldwide time trends in allergic disease symptoms in childhood: ISAAC Phases One and Three. Lancet. 2006;368:733-743. PMID 16935684
  8. Eagan TM, et al. The incidence of adult asthma: a review. Int J Tuberc Lung Dis. 2005;9:603-612. PMID 15971386
  9. Wu TJ, et al. Asthma incidence, remission, relapse and persistence: a population-based study in southern Taiwan. Respir Res. 2014;15:135. PMID 25387792
  10. Chen Y, et al. Sex difference in hospitalization due to asthma in relation to age. J Clin Epidemiol. 2003;56:180-187. PMID 12654413
  11. Merhej T, et al. Epidemiology of asthma: prevalence and burden of disease. Adv Exp Med Biol. 2023. PMID 37464114
  12. Asher I, Pearce N. Global burden of asthma among children. Int J Tuberc Lung Dis. 2014;18:1269-1278. PMID 25299857
  13. Pérez-Padilla R, et al. Understanding and preventing asthma-related deaths. Curr Opin Pulm Med. 2008;14:95-99. PMID 18797736
  14. Smith LB, et al. Black-White disparities in asthma hospitalizations and ED visits among Medicaid-enrolled children. Health Aff. 2024. PMID 38752291
  15. Binney S, et al. Trends in US pediatric asthma hospitalizations, by race and ethnicity, 2012–2020. JAMA Netw Open. 2024. PMID 39298796
  16. Pate CA, et al. Asthma surveillance — United States, 2006–2018. MMWR Surveill Summ. 2021;70:1-32. PMID 34529643
  17. Simoneau T, et al. Socioeconomic determinants of asthma health. Curr Opin Allergy Clin Immunol. 2023. PMID 36861771
  18. Pitchon RR, et al. Asthma mortality in children and adolescents of Brazil over a 20-year period. J Pediatr. 2020;96:432-438. PMID 31009618
  19. Kilpatrick K, et al. At-home asthma mortality unchanged despite declining mortality in other settings: US death certificate data, 2000–2019. J Allergy Clin Immunol Pract. 2024. PMID 37848103
  20. Khreis H, et al. Exposure to traffic-related air pollution and risk of development of childhood asthma: a systematic review and meta-analysis. Environ Int. 2017;100:1-31. PMID 27881237
  21. Agache I, et al. The impact of outdoor pollution and extreme temperatures on asthma-related outcomes: a systematic review for EAACI guidelines. Allergy. 2024. PMID 38311978
  22. Bahadori K, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24. PMID 19454036
  23. Ehteshami-Afshar S, et al. The global economic burden of asthma and chronic obstructive pulmonary disease. Clin Rev Allergy Immunol. 2016. PMID 26688525
  24. Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015;5 Suppl 1:S7-S10. PMID 26010063
  25. Gold DR, Wright R. Population disparities in asthma. Annu Rev Public Health. 2005;26:89-113. PMID 15760282
  26. Armeftis C, et al. An update on asthma diagnosis. J Clin Med. 2023;12. PMID 37358228